Lamotrigine Is Not Slow

Slides:



Advertisements
Similar presentations
Mirtazapine Flavio Guzmán, MD. Mirtazapine- Overview NaSSA (Noradrenergic and specific serotonergic antidepressant) H1 antagonist Sedation and weight.
Advertisements

Guy Brookes Leeds PFT.  Antipsychotic Medication  Antidepressant Medication  Mood Stabilisers  What does the Evidence mean?
1 Timing and Duration of Relapse Prevention Trials in Psychiatric New Drug Development David Michelson, M.D. Executive Director, Neuroscience Medical Research.
Evidence-based Treatment of Psychotic Depression Gregory W. Dalack, MD June 22, 2006.
Treating Bipolar Disorder in the Primary Care Setting
Réunion Ambulatoires SAS,  Similarly, a statistically significant MADRS reduction over time was found (F=156.2, p 800 mg/day) and low (
2007. Statistics  2-4 new cases per 100,000/year  1 in 200 people will have an episode of hypomania  Peak age of onset yrs  May have had a previous.
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
1 Bipolar Disorders: Therapeutic Options James W. Jefferson, M.D. Clinical Professor of Psychiatry University of Wisconsin School Of Medicine and Public.
Bipolar I Disorder Treatment. Therapeutic Goals Relief of immediate symptoms Improvement of patient’s well-being Elimination of stressors Combined pharmacotherapy.
Treatment for Adolescents With Depression Study (TADS)
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
FDA Hearing on Suicide and Antidepressants Presentation by Charles F. Reynolds, III, MD UPMC Professor of Geriatric Psychiatry University of Pittsburgh.
Psychotherapies in Treatment of Depression Copyright © World Psychiatric Association.
Treatment Resistant Pediatric BD Elham Shirazi M.D. Board of General Psychiatry Board of Child & Adolescent Psychiatry.
BIOLOGICAL THERAPIES FOR DEPRESSION – ELECTROCONVULSIVE THERAPY (ECT) ALICIA.
Affective Disorders. Who can tell me how many people suffer in America from bipolar disorder?” About 2 million people suffer and that is starting at 18.
If I’m on fire they dance around it and cook marshmallows. And if I’m ice they simply skate on me in little ballet costumes Anne Sexton was a poet born.
Long-Term Efficacy Data for Psychiatric Drugs Thomas Laughren, M.D. Director, Division of Psychiatry Products (HFD-130) PDAC Meeting (Oct 25, 2005)
BIPOLAR DISORDER, DR GIAN LIPPI CONSULTANT PSYCHIATRIST UNIVERSITY OF PRETORIA & WESKOPPIES HOSPITAL FORENSIC UNIT MANAGEMENT GUIDELINES.
Equal Access to ECT Hampered by Income and Attitudes Patricia Bradley RN PhD Jhansi Raj MD.
Date of download: 6/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Prospective, Randomized, Double-blind Comparison.
Objective: To describe the clinical effectiveness and cognitive effects of ECT in a large clinical sample of patients with schizophrenia and explore factors.
Waiting for the Psychiatry Consult Treatment of Suspected Bipolar Disorder in the FM Office Spring 2008 Karen S. Blackman, M.D., Department of Family Medicine,
Journal Club Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Rebecca Luke 2/9/2016.
Clinical Effectiveness and Cognitive Impact of Electroconvulsive Therapy for Schizophrenia: A Large Retrospective Study Tyler S. Kaster MD, Zafiris J.
Electroconvulsive Therapy (ECT) In Psychiatry today.
TRICYCLICS (TCA). HOW DO THEY WORK? Tricyclic antidepressants are used to treat depression and some other conditions. They often take 2-4 weeks to work.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Do antidepressants really work?
Ch. 19 S. 5 : Biological Therapy
Number Needed To Treat (NNT)
Module 3 Use of antipsychotics for unipolar depression
Module 3 Indications for Antipsychotics Bipolar Disorder
Politis A, Theleritis C, Soldatos C, Psarros C, Papadimitriou GN
Confidence Intervals and p-values
Eli Lilly’s Experimental Alzheimer’s Drug Fails in Large Trial
Qualitative Research Results Conclusions
S. Khaldi MD, C. Kornreich MD Phd Service de Psychiatrie.
for the Psychiatry Clerkship
Module 19 Mental Health Revised.
Lithium: Clinical Uses and Pharmacokinetics
Michael Panzer, MD ThedaCare Behavioral Health
Introduction to bipolar disorder
Other drugs used in the treatment of bipolar disorder
Bipolar Depression Pharmacotherapy: Part 1
Bipolar Disorder: Latest Clinical Update
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Lurasidone Flavio Guzmán, MD.
Insomnia pharmacotherapy: Off-label antipsychotics
Antidepressants for Bipolar Depression: Answering Clinical Questions
Six Microskills for Clinical Teaching
Dialogue Basics.
Bipolar Disorder Bipolar Disorder Alex Dudash.
Scientific Update.
Cornell Notes Note-taking strategy that will
The Challenges of Bipolar Disorders
What we are Saying Anne Cooke.
Obsessive-Compulsive Disorder: Pharmacotherapy
Major classes of drugs to reduce lipids
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Module 3 Indications for Antipsychotics Bipolar Disorder
Who suffers from Depression?
Dr James Ovens Consultant Psychiatrist Tandridge CMHRS
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Presentation transcript:

Lamotrigine Is Not Slow James Phelps, MD Director Mood Disorders Program Samaritan Mental Health, Corvallis, OR.

How Slow Is Lamotrigine? Change from baseline to each treatment visit in Mean MADRS Total Score (with 95% confidence interval bars) But again, then how slow is lamotrigine? Like you see that patient who has severe depression and you want this to work fast. How slow is lamotrigine? It has the reputation for being because of its long titration, six to eight weeks depending on how you do it. So it has a reputation for being slow. I’ve heard people say: “Well, we don’t use lamotrigine on our inpatient psychiatric unit because it’s too slow” which strikes me as rather ironic because wait a minute, don’t you start antidepressants on your inpatient psychiatric unit? Well, we all expect that a full trial of an antidepressant to rule whether it’s effective or not can take six or some people would even say eight weeks. So if it makes sense to start an antidepressant on an inpatient unit, it really makes sense to start lamotrigine on an inpatient unit. Nevertheless, it does have this reputation for being slow. In fact, people go on to use something that they think is faster like quetiapine say or even lithium. ---  So the irony is that lamotrigine is not so slow to produce a benefit. So there was a randomized trial in which it went head to head with olanzapine/fluoxetine combination. The study was sponsored by Eli Lilly who make olanzapine/fluoxetine combination. So you would expect that maybe they would kind of stack the deck against lamotrigine and they did in a number of interesting ways. Olanzapine/fluoxetine got to start faster. Lamotrigine had to do with its usual titration. ----  But interestingly, even though lamotrigine was always less effective than the olanzapine/fluoxetine combination, it was never as good but it was just as fast as the combination. In other words, the curve of improvement is not quite superimposed on that of olanzapine/fluoxetine combination. It’s parallel to it from the very beginning. So instead of waiting and waiting and waiting and then finally it kicks in, no. The benefits were paralleling the improvement on olanzapine/fluoxetine combination just not quite as good.   So it’s not that slow at least based on that study. So I think it makes sense to start lamotrigine where you would think of starting an antidepressant. It’s not that slow. Less effective Brown, E. B., McElroy, S. L., Keck Jr, P. E., Deldar, A., Adams, D. H., Tohen, M., & Williamson, D. J. (2006). A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. The Journal of clinical psychiatry, 67(7), 1025-1033. 

If not immediately dangerous Consider lamotrigine Bipolar depression ECT Now, in severe bipolar depression, if a patient’s life is at stake and using a treatment with robust evidence for efficacy instead of lamotrigine would make sense like electroconvulsive therapy/ECT for example or maybe quetiapine which can be quite fast, maybe even olanzapine/fluoxetine combination because the evidence for efficacy for those agents is better. And patients in the middle of the mood spectrum can have depressions that are this severe. But patients in that middle of the spectrum, they likely had these depressions many times before and they face the prospect of having them again unless a treatment is found that will prevent recurrences, in other words, a maintenance agent. --- So unless the depression is immediately dangerous, to me, it does not make sense to hurry toward a treatment with significant side effects like memory impairment with ECT or metabolic risks with quetiapine or olanzapine and skip over in the process a treatment with few side effects and no established long-term risks. Most patients in my practice prefer to work their way through options starting with those that if they work will be the most tolerable in the long run even if the likelihood of response is lower. If lamotrigine doesn’t work in six weeks when you’ve reached at least 100 mg, okay, then move on. Quetiapine Robust evidence OFC If not immediately dangerous Consider lamotrigine Phelps, J. R. (2016). A spectrum approach to mood disorders: not fully bipolar but not unipolar: practical management. New York: W. W. Norton & Company.

Key Points Lamotrigine is not much slower than antidepressants to produce benefits To summarize, key points here. Lamotrigine is not much slower than antidepressants. But if the patient has dangerous severe symptoms, use something that’s likely to be faster like ECT or olanzapine/fluoxetine combination even though I think lamotrigine is not far behind on that one. And otherwise, patients, again, they tend to choose based on tolerability not speed. If the patient has dangerously severe symptoms, other treatmetns like ECT and olanzapine are much faster Patients tend to choose medication based on tolerability, not speed

Next Presentation: Clinically Relevant Drug-Drug Interactions